Development
ImmunoPrecise Antibodies Ltd.
IPA
$0.6724
-$0.0296-4.22%
NASDAQ
| 10/31/2023 | 07/31/2023 | 04/30/2023 | 01/31/2023 | 10/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 64.96% | 63.35% | -3.30% | -15.44% | -38.60% |
| Total Depreciation and Amortization | -10.90% | -16.75% | 320.12% | 38.26% | 47.55% |
| Total Amortization of Deferred Charges | -- | -- | -75.43% | -- | -- |
| Total Other Non-Cash Items | 228.44% | 44.78% | 1,584.30% | -99.80% | -103.87% |
| Change in Net Operating Assets | -54.87% | 120.94% | -202.97% | 84.45% | 52.01% |
| Cash from Operations | 93.84% | 93.44% | -16.93% | 35.41% | -75.56% |
| Capital Expenditure | 58.07% | -47.25% | -204.28% | 51.30% | -494.79% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 100.00% | -- | 100.46% | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -112.65% | -- | 100.00% | 109.35% | -- |
| Cash from Investing | 74.68% | -113.44% | 89.85% | 68.00% | -927.97% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -1.64% | -49.45% | -46.92% | -59.92% | -33.19% |
| Issuance of Common Stock | -- | -- | -99.97% | -47.85% | 60.45% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -256.58% | -157.07% | -111.64% | -419.11% | 123.62% |
| Foreign Exchange rate Adjustments | -74.77% | -42.96% | 107.40% | -40.61% | 281.02% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 83.37% | 86.03% | 5.76% | 34.63% | -68.60% |